Evaxion Biotech A/S (EVAX): Price and Financial Metrics


Evaxion Biotech A/S (EVAX): $1.90

0.01 (+0.53%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EVAX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

EVAX Stock Price Chart Interactive Chart >

Price chart for EVAX

EVAX Price/Volume Stats

Current price $1.90 52-week high $25.04
Prev. close $1.89 52-week low $1.51
Day low $1.80 Volume 70,000
Day high $2.00 Avg. volume 272,775
50-day MA $2.66 Dividend yield N/A
200-day MA $4.81 Market Cap 44.09M

Evaxion Biotech A/S (EVAX) Company Bio


Evaxion Biotech A/S operates as a biotechnology company. The Company develops AI-immunology platform for decoding human immune system to discover and develop immunotherapies for cancer and infectious diseases treatment. Evaxion Biotech serves patients in Denmark.


EVAX Latest News Stream


Event/Time News Detail
Loading, please wait...

EVAX Latest Social Stream


Loading social stream, please wait...

View Full EVAX Social Stream

Latest EVAX News From Around the Web

Below are the latest news stories about Evaxion Biotech A that investors may wish to consider to help them evaluate EVAX as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, trader!

William White on InvestorPlace | January 27, 2022

Evaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading into Phase 2b in Collaboration with Merck

COPENHAGEN, Denmark, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a paper on personalized therapy with EVX-01 in patients with metastatic melanoma in the open access, peer-reviewed journal OncoImmunology. The paper, entitled, “Personalized therapy with peptide-based neo

Yahoo | January 26, 2022

Evaxion Biotech AS Sponsored ADR (EVAX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Evaxion Biotech AS Sponsored ADR (EVAX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Yahoo | January 25, 2022

Nasdaq’s European Markets Delivered Record Year in 2021

- Solidified Nasdaq position as the leading European listings hub with 219 new equity listings, including a record number of 174 initial public offerings (IPOs), raising a total of EUR 13.4 billion- Retail inflow and large interest in SME trading spurred all-time high levels in equity and derivative trading- Continued to lead in ESG with venture investment in Puro.earth and new product launches STOCKHOLM, Sweden, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) announced today that Nasdaq

Yahoo | January 21, 2022

Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA® for Treatment of Melanoma

COPENHAGEN, Denmark, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today it has received clearance from the Australia Therapeutic Goods Administration to initiate a Phase 2b trial of its patient specific cancer immunotherapy EVX-01 in combination with Merck & Co., Inc.’s (known as MSD outside th

Yahoo | January 18, 2022

Read More 'EVAX' Stories Here

EVAX Price Returns

1-mo -32.14%
3-mo -37.50%
6-mo -59.23%
1-year -71.81%
3-year N/A
5-year N/A
YTD -57.01%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7222 seconds.